mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity

 mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity

mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity

Shots:

  • mAbxience will equip their state-of-the-art cGMP facility in Spain with an ABEC 4,000L CSR Bioreactor
  • The system will be commissioned mid-2021 and will increase biosimilar and CDMO manufacturing capacity at the León site
  • The 4,000L volume & performance comparable to stainless steel systems will enable mAbxience to improve flexibility, productivity and efficiency. The CSR bioreactor design also allows for seamless scale-up and transfer of cell culture processes, thereby reducing time to market for mAbxience’s products

Click here to­ read full press release/ article | Ref: Businesswire | Image: mAbxience

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post